<DOC>
	<DOCNO>NCT00381134</DOCNO>
	<brief_summary>Kidney disease affect one three people diabetes mellitus , common medical problem . Treatment kidney disease medication low blood pressure slow kidney disease know cure . This study design test hypothesis certain combination-based blood pressure lower regimen ( FDA approve medication ) good single agent-based regimen lower blood pressure slow prevent progression incurable disease</brief_summary>
	<brief_title>Improving Outcomes Patients With Kidney Disease Due Diabetes</brief_title>
	<detailed_description>The long-range objective project prevent progression diabetic nephropathy , lead cause end-stage renal disease ( ESRD ) . In patient diabetic nephropathy progress inexorably ESRD despite inhibition renin-angiotensin- aldosterone system angiotensin convert enzyme inhibitor ( ACEIs ) angiotensin II type 1 receptor blocker ( ARBs ) . The specific aim proposal : 1 ) recruit multiethnic cohort 78 young adult ( age 20-40 ) type 1 ( n=36 ) type 2 ( n=36 ) diabetes overt nephropathy ( defined urine albumin/creatinine ratio &gt; 300 mg albumin/g creatinine ) randomize double blind fashion control group consist ACEI-based therapy alone ( ramipril 40 mg daily ) one two experimental group : ) ACEI + ARB ( ramipril 40 mg daily plus losartan 100 mg daily ) b ) ACEI + mineralocorticoid receptor antagonist ( MRA ) ( ramipril 40 mg daily plus spironolactone 25 mg daily ) ; 2 ) conduct 12-month prospective study determine proteinuria reduce great extent either ARB MRA add ACEi-based therapy . This study power detect 30 % great reduction 24-hour urine albumin/creatinine ratio either experimental group versus control ( alpha = 0.05 , beta=0.10 , repeat measure analysis variance ) . Secondary endpoint examine include : ( ) serum potassium creatinine ass safety , ( b ) TGF-beta , surrogate marker ongoing renal injury , ( c ) plasma renin activity , angiotensin II aldosterone level ( ) plasma lipid lipoprotein composition ; 3 ) perform repeat ambulatory blood pressure monitoring ( ABPM ) examine renoprotective effect 3 different regimen comparable 24-hour BP &lt; 125/75 mmHg . The deliverable include : 1 ) documentation safety maximal dose combination therapy ; 2 ) feasibility utilize 24-hr ABPM establish BP independent renoprotective effect specific antihypertensive therapy ; 3 ) provide preliminary data future large-scale study test efficacy safety combine ACEi MRA therapy renal outcome .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Adult male female subject age 2065 ethnic background . Type I diabetes mellitus define sudden onset insulin require diabetes prior age 20 least 5 year duration Type 2 diabetes mellitus define onset &gt; 20 year age treatment oral hypoglycemic agent and/or insulin increase Cpeptide level . Seated SBP &gt; 130 mmHg document one screen visit treat SBP &lt; 130 mmHg document history SBP &gt; 130 mmHg one previous occasion Proteinuria define 24hour urine albumin/creatinine ratio &gt; 300 mg/g ACE inhibitor without nonARB , nonaldosterone antagonist treatment Ongoing treatment ( &gt; 3 month ) ACE inhibitor ARB without additional antihypertensive therapy ( e.g . CCB , ablocker , bblocker , clonidine ) . BMI &gt; 45 kg/m2 Baseline serum creatinine &gt; 3.0 mg/dl female &gt; 4.0 mg/dl male creatinine clearance &lt; 20 ml/min estimate CockcroftGault equation ( base age , fast serum creatinine concentration ideal body weight kilogram ) . Secondary cause kidney disease diabetic nephropathy Serum potassium concentration &gt; 5.5 mEq/L ACE inhibitor therapy 710 day prior randomization Poorly control diabetes , i.e . HgbA1C &gt; 11 mg/dl 710 day prior randomization History allergy iothalamate history renal failure due contrast nephropathy Stroke myocardial infarction within precede 12 month prior randomization Coronary revascularization procedure within past 6 month Clinically apparent congestive heart failure define clinical sign heart failure ejection fraction &lt; 40 % ( and/or depress LV systolic function echocardiogram ) . Terminal disease include cancer AIDS Documented increase serum creatinine &gt; 50 % baseline within 3 month prior runin period Renal disease know opinion investigator cause condition diabetes Known adverse reaction study medication include ACE inhibitor , ARB spironolactone History chronic intermittent gross hematuria Spontaneous 24hour urine sodium excretion rate exceed 350 mEq/day AST ALT great 2.5 upper limit normal laboratory Pregnancy History autoimmune disease , connective tissue disease multiple drug allergy Anticipated need renal replacement therapy within 12 month Inclusion criterion normal subject Adult male female subject age 2065 ethnic background Exclusion criterion normal subject Chronic medical condition , include limited diabetes mellitus , hypertension , chronic kidney disease , hyperlipidemia . Use medication antihypertensive Inability follow study protocol reason</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>double-blind</keyword>
	<keyword>placebo-controlled</keyword>
	<keyword>nephropathy</keyword>
	<keyword>blood pressure</keyword>
	<keyword>urine albumin creatinine ratio</keyword>
	<keyword>placebo</keyword>
</DOC>